Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
DHR Catalyst Timeline
Dated clinical, regulatory and corporate events for Danaher Corporation
Past FDA Catalysts and PDUFA Decisions
How DHR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Drug Pipeline Intelligence
No drug pipeline
Danaher Corporation is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every DHR program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Milosevich Gregory MOfficer (Executive Vice President) | Sell | -2,100 22,367 held | $230.62 | 11/09/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in DHR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RTW INVESTMENTS, LP | 0.5 % (25 %) | 50.96 M | 230.00 K |
Ownership Trends
DHR Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How DHR ranks across every disease it competes in
DHR News
Danaher to Present at UBS Global and Jefferies Global Healthcare Conferences
Danaher Corporation announced that CEO Julie Sawyer Montgomery will present at the UBS Global Healthcare Conference on November 9, 2026, and the Jefferies Global Healthcare Conference on November 17, 2026. Both presentations will be available via webcast. Danaher continues to lead in life sciences and biotechnology innovation.
Read more →Danaher Reports Third Quarter 2026 Results
Danaher Corporation reported strong third quarter results for 2026, with net earnings of $1.2 billion, a 34.5% increase from the previous year. Revenues reached $6.6 billion, reflecting an 8.5% year-over-year growth. The company also raised its full-year adjusted diluted net earnings guidance, indicating positive financial momentum.
Read more →Danaher Collaborates with NVIDIA to Advance Autonomous Science
Danaher Corporation has announced a collaboration with NVIDIA to enhance autonomous science by integrating AI technologies with scientific instruments. This partnership aims to streamline laboratory workflows and accelerate scientific discovery, allowing researchers to transition from predictions to experimental evidence more efficiently. The initiative reflects Danaher's commitment to innovation in AI-enabled science.
Read more →Danaher Announces Appointments of Daniel Comas and Robert Hershberg to Board of Directors
Danaher Corporation has appointed Daniel L. Comas and Robert Hershberg, M.D., Ph.D., to its Board of Directors, expanding the Board from 11 to 13 members. Comas brings extensive experience from his tenure at Danaher, while Hershberg adds significant scientific and biopharmaceutical expertise. Alan G. Spoon will retire from the Board at the 2027 Annual Meeting.
Read more →Danaher Accelerates Life Sciences Research with New AI-powered Autonomous Lab
Danaher Corporation has announced the launch of its first AI-powered autonomous lab, aimed at accelerating the development of custom antibodies and molecular tools. Set to operate at scale in early 2027, the lab will utilize AI and robotics to enhance research efficiency, enabling up to eight times faster discovery of affinity reagents. This initiative is part of a broader strategy to integrate smart instruments and workflows in scientific research.
Read more →Julie Sawyer Montgomery Assumes Role as Danaher President and Chief Executive Officer
Julie Sawyer Montgomery has officially taken on the roles of President and CEO of Danaher Corporation, effective October 1, 2026. She has been with the company since 2017, holding various leadership positions that have contributed to its growth and innovation. Rainer Blair will assist in the transition as a senior advisor until March 31, 2027.
Read more →Danaher Schedules Third Quarter 2026 Earnings Conference Call
Danaher Corporation has scheduled its third quarter 2026 earnings conference call for October 21, 2026. The call will cover financial performance and future expectations, lasting approximately one hour. Investors can access the call via a dedicated phone line or through a webcast on Danaher's website, with a replay available afterward.
Read more →Danaher Announces Quarterly Dividend
Danaher Corporation has declared a quarterly cash dividend of $0.40 per share, set to be paid on October 30, 2026, to shareholders on record as of September 30, 2026. This announcement highlights Danaher's ongoing commitment to returning value to its shareholders while maintaining a focus on innovation in life sciences and diagnostics.
Read more →Danaher Appoints Julie Sawyer Montgomery as President and Chief Executive Officer
Danaher Corporation has appointed Julie Sawyer Montgomery as President and CEO, effective October 1, 2026, succeeding Rainer Blair, who will retire. Montgomery has been instrumental in growing Danaher's Diagnostics platform significantly since joining in 2017. Her leadership is expected to drive further innovation and growth within the company.
Read more →Danaher Reports Second Quarter 2026 Results
Danaher Corporation reported a strong second quarter for 2026, with net earnings rising 60% year-over-year to $870 million. Revenue also increased by 5.5% to $6.3 billion, driven by robust performance in the Life Sciences segment. The company has raised its full-year earnings guidance, reflecting optimism about continued growth despite some challenges in bioprocessing revenue.
Read more →Danaher Foundation Commits $1 Million to Ebola Outbreak Relief Efforts in Central Africa
The Danaher Foundation has pledged $1 million to support urgent Ebola outbreak relief efforts in Central Africa, specifically in the Democratic Republic of Congo and Uganda. The funding will be allocated to Save the Children, the International Rescue Committee, and the World Food Program to address critical needs such as infection prevention and emergency food assistance. This support aims to enhance the response to the ongoing outbreak, which has already confirmed over 1,000 cases.
Read more →Danaher Schedules Second Quarter 2026 Earnings Conference Call
Danaher Corporation has announced its quarterly earnings conference call for Q2 2026, scheduled for July 21, 2026. The call will cover the company's financial performance and future expectations. Interested parties can access the call via a dedicated phone line or through a webcast on Danaher's website. A replay will be available after the call.
Read more →Danaher to Present at Bank of America Securities Healthcare Conference
Danaher Corporation's CEO, Rainer M. Blair, will present at the Bank of America Securities Healthcare Conference on May 13, 2026. The event will take place in Las Vegas and will be available via webcast. Danaher is recognized for its innovative contributions to life sciences and diagnostics, aiming to enhance human health.
Read more →Danaher Announces Pricing of Euro-Denominated Senior Notes Offering
Danaher Corporation has announced the pricing of a euro-denominated senior notes offering totaling €2.98 billion. The offering includes various notes with different maturities and interest rates, aimed at funding the acquisition of Masimo Corporation. The closing of the offering is anticipated on April 29, 2026, pending customary conditions.
Read more →Danaher Reports First Quarter 2026 Results
Danaher Corporation reported strong first quarter results for 2026, with net earnings reaching $1.0 billion and a 9.5% increase in adjusted diluted earnings per share. Revenues rose 3.5% year-over-year, driven by growth in Bioprocessing and Life Sciences. The company also announced plans to acquire Masimo Corporation, which is expected to enhance its capabilities in patient monitoring. However, a lighter-than-expected respiratory season at Cepheid posed challenges.
Read more →Beckman Coulter Diagnostics Earns CE Mark for New Assay Delivering Bacterial vs. Viral Infection Results in Approximately 20 Minutes
Beckman Coulter Diagnostics has received CE mark approval for its Access MeMed BV assay, which allows for rapid differentiation between bacterial and viral infections in about 20 minutes. This assay can significantly reduce healthcare costs in Europe by minimizing unnecessary admissions and testing. By leveraging existing laboratory infrastructure, it aims to enhance clinical decision-making and support antimicrobial stewardship.
Read more →Danaher Schedules First Quarter 2026 Earnings Conference Call
Danaher Corporation has scheduled its first quarter 2026 earnings conference call for April 21, 2026, at 8:00 a.m. ET. The call will cover the company's financial performance and future expectations. A replay will be available after the call, along with related materials on Danaher's website.
Read more →Danaher to Present at TD Cowen Health Care Conference
Danaher Corporation announced that CEO Rainer M. Blair will present at the TD Cowen Healthcare Conference on March 3, 2025, at 1:50 p.m. ET. The event will be webcast live and accessible via Danaher's website. The company emphasizes its commitment to innovation in life sciences and diagnostics.
Read more →